Professor Ming Liang HE (何明亮教授)

Ph.D. Shanghai Institute of Biochemistry, The Chinese Academy of Sciences, Shanghai, China
Postdoctoral fellow, Washington University School of Medicine, St. Louis, USA

Associate Professor, Stanley Ho Centre for Emerging Infectious Diseases, School of Public Health and Primary Care
Department of Medicine & Therapeutics (joint appointment)


Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

MLHe_150.jpg 
Biography 

Professor He got his PhD training in Shanghai Institute of Biochemistry, The Chinese academy of Sciences, and postdoctoral training in Washington University School of Medicine at St. Louis, MO, USA.  He was an assistant professor (Research) in The University of Hong Kong (2000~2004) and was appointed as associate professor in 2005 in The Chinese University of Hong Kong. His research fields including molecular mechanisms of cancers, mechanisms of virus associated diseases, control and treatment of virus infection (HIV/HBV/HCV/SARS/avian flu), gene therapy, gene regulation, genetic polymorphism of diseases and drug development. Professor He has filed or obtained 6 US patents and published over 50 research papers in peer-reviewed international journals, including JAMA, PNAS, JNCI, Hepatology, and Cancer Res. .

Teaching Commitment

Providing PhD / MPhil training on molecular biology.  The research platform include: functional genomics, proteomics, RNA interference, gene therapy, cancer biology and animal models.

Research interests 
  • Cancer and infectious diseases caused by viruses (including hepatitis B/C virus, human immunodeficiency virus, SARS-coronavirus)
  • The dissection of the mechanism of these diseases
  • Development of therapeutic drugs (including agents for gene therapy) for the treatment of cancers and viral infections.
Student supervising
Liu Zheng (Ph.D, graduated);
Dong Qingming (Ph.D);
Zhu Lin (M. Phil);
Ma Yan (Ph.D)
Li Jun (Ph.D)
He Lai (Ph.D)
Zhao Jin (Ph.D)
Lu Jing (Ph.D) 
Competitive Research Grant Awarded
ITF (ITS/080/08, 2008-2010) Therapeutic TBX2/TBX3 antagonist peptide for treatment of multiple cancers. HK$1,000,000 (Principal Investigator)  
RGC (2007-2009) Functional Characterization of Novel HBV subgenotypes/Mutations Associated with Increased Risk for Hepatocellular Carcinoma (HCC). HK932,500 (Principal Investigator).   
RFCID (2007-2009) Super Interferon for the treatment of Bird flu (avian H5N1 influenza A). HK$800,000 (Co-I) 
AIDS Trust Fund (MSS143R, 2006-2007)  Establishment of HIV Replication capacity assay for enhancing management of AIDS patients in Hong Kong. HK$671,418  (Principal Investigator)   
AIDS Trust Fund (MSS144R, 2006-2007)    Novel Anti-HIVDrug: A cyclosporine Analog. HK$715,553  (co-investigator)  
RGC (2005-2007): Mechanisms of a novel HCC-associated Oncogene (HCAO) in Hepatocellular carcinogenesis.  HK$939,968. (Principal Investigator)  
ITF Fund  (2004-2005):  Gene therapy for the treatment of HBV infection and HBV-induced liver cancer. HK$1,680,000.  (Principal Investigator). 
RFCID Grants (2005-2007):   Development of  RNA interfering agents for inhibition of SARS associated coronaviris replication and infection. HK$804,572.  (Principal Investigator) 
ITF Grants (2004-2005):  Development of novel AAV based anti-angiogenesis gene therapy and cocktail therapy for the treatment of liver cancer. HK$2,220,000.  Co-Investigator. 
RGC/NSFC Grants (2003-2007): Functional characterization of Makorin-2 and its interacting proteins in Xenopus embryonic development. HK$600,000. Co-Investigator.  
RGC (2003-2007):  Transcriptional and Functional Regulation of TBX3 in Retina formation. Principal Investigator:  HK$624,000. Principal Investigator. 
Science and Technology Commission of Shanghai for Research Fund (2002-2004): Development of infectious HBV Mice Model using recombinant AAV Virus.  Principal Investigator: RMB600,000.  Principal Investigator. 
US patents  

Ming-Liang He, Hsiang-fu kung, Mariae C. Lin  A novel sensitive method for the quantification of HBV cccDNA by real-time PCR. ( No. 10/449,801).  

Ming-Liang He, Hsiang-fu Kung  Inhibition of Hepatitis B virus (HBV) replication by RNA interference (No. 7,067,249, issued by June 27, 2006).

Ming-Liang He, et al  Inhibition of  SARS-associated coronavirus infection and replication by RNA interference  (No.7,129,223, issued  by December 27, 2006).

Ming-Liang He, Marie Lin, Hsing-fu Kung. Gene Therapy of HBV Infection Via Adeno-Associated Viral Vector Mediated Long Term Expression of Small Hairpin RNA (shRNA).   U.S.CIP Patent Appl. No.11/415,876 (filed in May, 2006).  
Marie Lin, Shen Zan, …, Ming-Liang He, et al. Cocktail gene therapy using adenoassociated virus (AAV) carrying a novel anati-angiogenesis gene, HGFK1, combined with adv-P53 or Adv-IL2 for the treatment of metastasis cancer and methods related thereto.  (US patent filed). 
Selected Publications 

Xin wang, Yangchao Chen, Quan-bin Han, Hua Wang, Zheng Liu, Christopher Hon-ki Cheng, david T Yew, Marie CM Lin, Ming-Liang He, Hong-xi Xu, Joseph JY Sung, Hsiang-fu Kung. Proteomic Identification of Molecular targets of Gambogic acid: Role of Stathmin in Hepatocellular Carcinoma. Proteomics (in press) IF 5.5

Qingming Dong, Henry LY Chan, Zheng Liu, Yangchao Chen, Denise PC Chan, Bao Zhang, Hsiang-fu Kung, Joseph JY Sung, Ming-Liang He*. A1762T/G1764A Mutations of Hepatitis B virus, Associated with the Increased Risk of Hepatocellular Carcinoma, Reduce Basal Core Promoter Activities. Biochem Biophys Res Commun (in press)

Guo Li, Xiao-ai Zhang, Hua Wang, Chun-ling Meng, Chu-yan Chan, David Tai Wai Yew, Xin Wang, Kam Sze Tsang, Karen Li, Sau-na Tsai, Sai-ming Ngai, Zhong-chao Han, Marie Chia-mi Lin, Ming-liang He, and Hsiang-fu Kung. Comparative proteomic analysis between umbilical cord and bone marrow derived mesenchymal stem cells: implications in the migration of human mesenchymal stem cells. Proteomics (in press) IF: 5.5

Zheng Liu, Yuanming Sun, Qingmin Dong, Mingliang He , Christopher H. K. Cheng, Feiyue Fan. A novel, TSHR gene mutation (Ile691Phe) in a Chinese family causing autosomal dominant non-autoimmune hyperthyroidism. Journal of human genetics (in press) IF 2.3

Pai-Hao Yang, William K.C. Cheung, Ying Peng, Ming-Liang He, Guo-Qing Wu, Dan Xie, Bing-Hua Jiang, Qiu-Hua Huang, Zhu Chen, and Hsiang-Fu Kung. Makorin-2 is a neurogenesis inhibitor downstream of PI3k/AKT signal. J Biological Chemistry 2008; 283(13):8486-8495. IF 5.3

Bing Liang*, Ming-Liang He*, Zhong- Peng Xiao, Yi Li, Chu-yan Chan, Hsiang-Fu Kung, Xin-Tao Shuai, Ying Peng. Synthesis and characterization of folate-PEG-grafted-hyperbranched-PEI for tumor-targeted gene delivery. Biochem Biophys Res Commun 2008; 367( 4): 874-880. IF 2.9

Zhi Li, Hong Yao, Yan Ma , Qingming Dong, Yangchao Chen, Ying Peng, Bo-jian Zheng, Jian-dong Huang, Chu-yan Chan, Marie C. Lin, Joseph J Sung, Kwok Yun Yuen, Hsiang-fu Kung*, Ming-Liang He*. Inhibition of HBV gene expression and replication by stably expressed interferon-α1 via adeno-associated viral vectors J. Gen. Med 2008; 10(6):619-627. IF 3.92

Zan Shen, Zhen Fan Yang, Yi Gao, Ji-Cheng Li, Ching Chiu Liu, Wayne D Hsueh, Randy Poon, Sheng Tat Fan, Ying Peng, Tsai-ping Li, Ren-bao Gan, Ming-Liang He, Hsiang-fu Kung, Marie CM Lin. The Kringle 1 Domain of Hepatocyte Growth factor has antiangiogenic and antitumor Cell effects on Hepatocellular carcinoma. Cancer Research 2008; 68(2):404-414. IF 8.1.

Yan Ma, Chu-yan Chan, Ming-Liang He*. RNA interference and antiviral therapy World J. Gastroenterology 2007; 13:5169-5179 (Editorial).

Nan Yang, Julian A. Tanner, Bo-Jian Zheng, Rory M. Watt, Ming-Liang He , Lin-Yu Lu, Jie-Qing Jiang, Ka-To Shum, Yong-Ping Lin, Kin-Ling Wong, Marie C. M. Lin, Hsiang-Fu Kung, Hongzhe Sun, and Jian-Dong Huang. Bismuth Complexes Inhibit the SARS Coronavirus . ANGEWANDTE CHEMIE-Internation Edit 2007; 46:6464-6468. IF 10.2

Yangchao Chen, Marie Chia-mi Lin, Hua Wang, Chu-yan Chan, Lei Jiang, Sai Ming Ngai, Jun Yu, Ming-Liang He, Pang-Chui Show, David T Yew, Joseph J Sung, Hsiang-fu Kung. Proteomic analysis of EZH2 downstream proteins in hepatocellular carcinoma. Proteomic 2007; 7(17):3097-3104. IF 6.1

Samuel S. M. Ng, Yuen-Ting Cheung, Ming Li, Xiao-Meng An, Gloria Hoi-Yee Li, William Cheung, Johnny Sze, Lihui Lai, Ming-Liang He , Ying Peng, Harry H. X. Xia, Benjamin C. Y. Wong, Suet-Yi Leung, Hsiang-Fu Kung, and Marie C. Lin. Cell cycle related kinase , a novel candidate oncogene in human glioblastoma JNCI 2007 99:936-948. IF:15.27

Guofa Liu, Weiquan Li, Xue Gao, Xiaoling Li, Claudia Jürgensen, Hwan-Tae Park, Nah-Young Shin, Jian Yu, Ming-Liang He, Steven K. Hanks, Jane Y. Wu, Kun-Liang Guan , Yi Rao. p130 CAS is required for Netrin signaling and commissural axon guidance. J Neuroscience 2007; 27:957-968. IF: 8.3

Chen Y , Lin MC, Yao H, Wang H, Zhang AQ, Yu J, Hui CK, Lau GK, He ML, Sung J, Kung HF. Lentivirus-mediated RNA interference targeting EZH2 inhibits hepatocellular carcinoma growth via down-regulation of stathmin. Hepatology 2007; 46(1):200-208. IF: 10.45.

Ming-Liang He , Che-Kit Lin, Kenneth Tong, Bingying Xu, Joseph JY Sung, Hsiang-fu Kung, Shui Shan Lee. Absence of CYP2B6 promoter -82T>C mutation in Chinese as an additional factor for slow metabolism of drugs commonly used in infections. European Journal of Clinical Pharmacology 2006; 62:585-586. IF: 2.08

Kenneth Tong, Ming-Liang He, Lin CK, Liping Guo, Hsiang-fu Kung, Joseph J Sung, Shui Shan Lee. The implications of a high allelic frequency of CYP2B6 G516T in ethnic Chinese. Clin. Infect. Dis 2006; 43:541-542. IF: 6.49

Ming-Liang He , Bo-jian Zheng, Ying Chen, Kin-Ling Wong, Jian-Dong Huang, Marie C. Lin, Ying Peng, Kwok Y. Yuen, Joseph JY Sung, Hsiang-fu Kung. Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus. FEBS Lett 2006; 580(10):2414-2420. IF: 3.84

Xiang-Ping Li, Christine Y.S. Li, Xiaohua Li, Yanqing Ding, Lally L.Y. Chan, Pai-Hao Yang, Gang Li, Xong Liu, Jennifer S. Lin, Jide Wang , Ming-liang He, Hsiang-fu Kung, Marie C. Lin and Ying Peng. Inhibition of Human Nasopharyngeal Carcinoma Growth and Metastasis in Mice by Adenovirus-associated Virus Mediated Expression of Human Endostatin Molecular Cancer Therapeutics 2006; 5(5):1290-1298. IF:5.2

Ming-Li, Samuel Sai-ming Ng, Jide Wang, Lihui Lai, Suet Yi Leung, Michel Franco, Ying Peng, Ming-liang He, Hsiang-fu Kung, and Marie Chia-mi Lin. EFA6A enhances glioma cell invasion through ARF6/ERK signaling. Cancer Res 2006; 66(3):1583-1590. IF: 8.5

Bo-Jian Zheng, Yi Guan, Ming-Liang He, Hongzhe Sun, Lanying Du, Ying Zheng, Kin-Ling Wong, Honglin Chen, Ying Chen, Linyu Lu, Julian A Tanner, Rory M Watt, Neri Niccolai, Andrea Bernini, Ottavia Spiga, Patrick CY Woo, Hsiang-fu Kung, Kwok-Yung Yuen, Jian-Dong Huang. Synthetic peptides outside the spike protein hepted repeat regions as potent inhibitors of SARS-associated coronavirus. Ativiral Therapy 2005; 10:375-385. IF: 6.1

Julian A. Tanner, Rory M. Watt, Lan Jin, Bo-Jian Zheng, Ming-Liang He , Lin-Yu Lu, Yi Guan, Ying Chen, Marie C. M. Lin, Hsiang-Fu Kung, Hong-Zhe Sun, Jian-Dong Huang. The Adamantane-Derived Bananins are Potent Inhibitors of the Helicase Activities and Replication of SARS Coronavirus. Chemistry & Biology 2005; 12(3):303-311 IF: 6.1.
 

Ying Peng, K.H.H. Kwok, Pai-Hao Yang, Samuel S.M. Ng, Jie Liu, O.G. Wong, Ming-Liang He, Hsiang-Fu Kung and Marie C.M. Lin. Ascorbic acid inhibits ROS production, NF-kappaB activation and prevents ethanol-induced growth retardation and microencephaly. Neuropharmacology 2005; 48(3):426-434. IF: 3.8

Bernini A, Spiga O, Ciutti A, Chiellini S, Bracci L, Yan X, Zheng B, Huang J, He ML, Song HD, Hao P, Zhao G, Niccolai N. Prediction of quaternary assembly of SARS coronavirus peplomer. Biochem Biophys Res Commun 2004; 325(4):1210-1214. IF2.9

Peng Y, Jiang BH, Yang PH, Cao Z, Shi X, Lin MC, He ML, Kung HF. Phosphatidylinositol-3 kinase signaling is involved in neurogenesis during Xenopus embryonic development. J Biol Chem 2004; 279:28509-28514. IF: 6.7

Bojian Zheng*, Ming-Liang He*, King-Ling Wong, Ching Tung Lum, Leo L.M. Poon, Ying Peng, Yi Guan, Marie C.M. Lin, Hsiang-fu, Kung. Potent Inhibition of SARS-Associated Coronavirus (SCoV) Infection and Replication by Type I Interferons (IFNα/β) but not by Type II Interferon (IFNγ) J. Interferon Cytokine Res 2004. 24, 388-390. (* co-first author). IF 2.1

Ying Peng; pai Hao Yang; Oscar G, Wong; Samuel S. M. Ng; Jie Liu; Ming-Liang He; Hsiang-fu Kung; Marie C. M. Lin. Critical role of Pax6 in alcohol-induced fetal microcephaly. Neurobiology of Disease 2004; 16:370-376. IF: 5.2

Ying Chen, Johnny Sze, Ming-Liang He *. The occurrence of HBV cccDNA in the patients’ sera is an indicator for HBV reactivation and an early signal of liver damage. World J. Gastroenter 2004; 10:82-85. IF: 3.3

Ying Peng, Pai-Hao Yang, Yan Guo, Samuel S.M.Ng, Jie Liu, P.C.W. Fung, David Tay, Jian Ge, Ming-Liang He, Hsiang-fu Kung, Marie C. Lin. Catalase and Peroxiredoxin 5 Protect Xenopus Embryos Against Alcohol-induced Ocular Anomalies. Investigative Ophthalmology & Visual Science 2004; 45:23-29. IF: 4.1

Bo-jian Zheng, Yi Guan, Qingquan Tang, Du Cheng, Frank Y. Xie, Ming-Liang He , Kwok-Wah Chan, Kin-Ling Wong, Eric Lader, Martin C.Woodle, Patrick Y. Lu, Baojian Li , and Nanshan Zhong. Prophylactic and Therapeutic Effects of Small Interfering RNA Targeting SARS-oronavirus .Antiviral Therapy 2004; 9:365-374. IF: 6.5.

Ming-Liang He, Bojian Zheng, Ying Peng, Joseph S.M. Peiris, Leo L.M. Poon, Kwok Y Yuen, Marie C.M. Lin, Hsiang-fu Kung; Yi Guan. Inhibition of SARS-Associated Coronavirus Infection and Replication by RNA Interference. JAMA 2003; 290:2665-2666. IF: 23.18

Ying Chen, Dan Du, Jun Wu, Chun-Pong Chan, Tan Yueqiu, Hsiang-fu Kung, Ming-Liang He*. Inhibition of hepatitis B virus (HBV) replication by stably-expressed shRNA. Biochem Biophys Res Commun 2003; 311: 398-404. IF: 3.0

 
[ Back ]